rolipram has been researched along with Innate Inflammatory Response in 54 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " As a selective phosphodiesterase-4 inhibitor, rolipram also exhibits the abilities of inhibiting multiple pro-inflammatory cytokines production in macrophages and toxin-induced inflammation in mice." | 7.96 | Rolipram Protects Mice from Gram-negative Bacterium Escherichia coli-induced Inflammation and Septic Shock. ( Chen, X; Jiang, Y; Lu, X; Pan, ZK; Wang, J, 2020) |
| "PPE-SVC and viscolin attenuate airway inflammation and eosinophil infiltration in OVA-sensitized mice." | 7.77 | Partially purified extract and viscolin from Viscum coloratum attenuate airway inflammation and eosinophil infiltration in ovalbumin-sensitized mice. ( Chiang, MS; Huang, WC; Hwang, TL; Kuo, ML; Leu, YL; Liou, CJ; Shen, JJ, 2011) |
| "The aim of this study was to evaluate the influence of pretreatment with the phosphodiesterase-4 inhibitor rolipram on pulmonary resistance, influx of inflammatory cells, and histamine concentration in bronchoalveolar lavage fluid (BALF) during an experimental asthmatic reaction induced in ovalbumin (OA)-sensitized guinea pigs, challenged with OA inhalation." | 7.73 | Effects of the phosphodiestrase-4 inhibitor rolipram on lung resistance and inflammatory reaction in experimental asthma. ( Chazan, R; Glapiński, J; Grubek-Jaworska, H; Hoser, G; Nejman-Gryz, P, 2006) |
| " As a selective phosphodiesterase-4 inhibitor, rolipram also exhibits the abilities of inhibiting multiple pro-inflammatory cytokines production in macrophages and toxin-induced inflammation in mice." | 3.96 | Rolipram Protects Mice from Gram-negative Bacterium Escherichia coli-induced Inflammation and Septic Shock. ( Chen, X; Jiang, Y; Lu, X; Pan, ZK; Wang, J, 2020) |
| " In preclinical models, the therapeutic index as defined in a rodent lung inflammation model versus rat pica feeding was >150 compared with 0." | 3.80 | GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species. ( Arban, R; Cavallini, P; Davies, CH; Davis, TG; Gray, FA; Montanari, D; Negri, M; Poffe, A; Rutter, AR; Schneck, J; Vicentini, E; Wren, PB, 2014) |
| "PPE-SVC and viscolin attenuate airway inflammation and eosinophil infiltration in OVA-sensitized mice." | 3.77 | Partially purified extract and viscolin from Viscum coloratum attenuate airway inflammation and eosinophil infiltration in ovalbumin-sensitized mice. ( Chiang, MS; Huang, WC; Hwang, TL; Kuo, ML; Leu, YL; Liou, CJ; Shen, JJ, 2011) |
| "Rat pups were placed under hyperoxia (FiO2>95%) or room air from birth, and received rolipram or its diluent daily until sacrifice." | 3.74 | Effects of phosphodiesterase 4 inhibition on alveolarization and hyperoxia toxicity in newborn rats. ( Boucherat, O; Bourbon, J; Delacourt, C; Evain-Brion, D; Franco-Montoya, ML; Jarreau, PH; Lopez, E; Méhats, C; Schmitz, T; Zana, E, 2008) |
| " As this experimental model of lung inflammation partially mimics some features of chronic obstructive pulmonary disease (COPD), we have investigated the effects of treatment by anti-inflammatory compounds, dexamethasone and rolipram and a non-specific matrix metalloproteinase (MMP) inhibitor, marimastat." | 3.74 | Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. ( Berna, P; Bertrand, CP; Boichot, E; Hitier, S; Lagente, V; Nénan, S; Planquois, JM, 2007) |
| " In this study we investigated the effects of rolipram, a selective phosphodiesterase type 4 inhibitor, on 14C-deoxyglucose (DG) uptake in inflammatory lesions and other normal tissues, and attempted to improve the inflammation/muscle ratio." | 3.73 | Effect of rolipram on relative 14C-deoxyglucose uptake in inflammatory lesions and skeletal muscle. ( Gee, A; Hosoi, R; Inoue, O; Nishimura, T; Shukuri, M; Terai, M, 2005) |
| "The aim of this study was to evaluate the influence of pretreatment with the phosphodiesterase-4 inhibitor rolipram on pulmonary resistance, influx of inflammatory cells, and histamine concentration in bronchoalveolar lavage fluid (BALF) during an experimental asthmatic reaction induced in ovalbumin (OA)-sensitized guinea pigs, challenged with OA inhalation." | 3.73 | Effects of the phosphodiestrase-4 inhibitor rolipram on lung resistance and inflammatory reaction in experimental asthma. ( Chazan, R; Glapiński, J; Grubek-Jaworska, H; Hoser, G; Nejman-Gryz, P, 2006) |
| "Using a rat model of lipopolysaccharide (LPS)-induced pulmonary inflammation, the antiinflammatory activity of SB 207499 was evaluated and compared to that of the prototypic type-4 phosphodiesterase (PDE4) inhibitor, rolipram." | 3.71 | Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia. ( Chapman, R; Fine, J; Jones, H; Kreutner, W; Kung, TT; Minnicozzi, M; Spond, J, 2001) |
| " The objective of the present paper was to evaluate the relevance of neuronal balance of cyclic AMP and cyclic GMP concentration for functional regulation of nociceptor sensitivity during inflammation." | 3.70 | Pharmacological modulation of secondary mediator systems--cyclic AMP and cyclic GMP--on inflammatory hyperalgesia. ( Cunha, FQ; Ferreira, SH; Teixeira, MM, 1999) |
| " We then report the in vivo anti-inflammatory effect of PDE-IV inhibition in five murine models of inflammation: (i) elevation of serum TNF-alpha induced by a sublethal LPS injection; (ii) LPS-induced endotoxic shock; (iii) LPS/galactosamine-induced endotoxic shock; (iv) carrageenan-induced paw oedema; and (v) adjuvant arthritis." | 3.69 | Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. ( Bateman-Fite, R; Brackeen, MF; Clark, RL; Connolly, KM; Menius, JA; Noel, LS; Sekut, L; Stimpson, SA; Yarnall, D, 1995) |
| "A new guinea pig model of allergic asthma was used to investigate the effects of low doses of the phosphodiesterase inhibitors, rolipram (phosphodiesterase IV selective), ORG 20241 (N-hydroxy-4-(3,4-dimethoxyphenyl)-thiazole-2-carboximidamide; dual phosphodiesterase III/IV inhibitor with some selectivity for the phosphodiesterase IV isoenzyme), and of theophylline (non-selective) on allergen-induced early and late phase asthmatic reactions, bronchial hyperreactivity to histamine inhalation, and airway inflammation." | 3.69 | Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs. ( Meurs, H; Olymulder, CG; Santing, RE; Van der Molen, K; Zaagsma, J, 1995) |
| " We have investigated the effects of RP 73401, a novel, potent and highly selective cyclic nucleotide phosphodiesterase (PDE) type IV inhibitor, in guinea-pig and rat models of bronchoconstriction and allergic inflammation." | 3.69 | Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. ( Battram, CH; Jordan, R; Lewis, SA; Raeburn, D; Sharma, S; Souness, JE; Tomkinson, A; Underwood, SL; Webber, SE; Woodman, VR, 1994) |
| " In vivo, rolipram inhibited arachidonic acid-induced inflammation in the mouse, while the low Km-cyclic-GMP PDE inhibitor, zaprinast, did not inhibit." | 3.68 | Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response. ( Breton, J; Griswold, DE; Marshall, PJ; Torphy, TJ; Webb, EF; White, JR, 1993) |
| "Inflammation is generally accepted as a component of the host defence system and a protective response in the context of infectious diseases." | 2.66 | Harnessing inflammation resolving-based therapeutic agents to treat pulmonary viral infections: What can the future offer to COVID-19? ( Pinho, V; Sousa, LP; Teixeira, MM, 2020) |
| "Since aging and inflammation affect cognition and are risk factors for AD, these aspects were also evaluated." | 1.48 | The location discrimination reversal task in mice is sensitive to deficits in performance caused by aging, pharmacological and other challenges. ( Graf, R; Hughes, ZA; Longo, JL, 2018) |
| "Rolipram treatment significantly attenuated STZ induced and age related memory deficits, biochemical and histopathological alterations." | 1.46 | Inhibitor of Phosphodiestearse-4 improves memory deficits, oxidative stress, neuroinflammation and neuropathological alterations in mouse models of dementia of Alzheimer's Type. ( Kumar, A; Singh, N, 2017) |
| "Treatment with rolipram blocked LPS-induced Ca(2+) increase and ROS production." | 1.43 | The Regulatory Role of Rolipram on Inflammatory Mediators and Cholinergic/Adrenergic Stimulation-Induced Signals in Isolated Primary Mouse Submandibular Gland Cells. ( Hong, JH; Lee, DU; Shin, DM, 2016) |
| "Paw edema was induced in male Swiss mice (20-30 g) by subplantar injection of carrageenan (0." | 1.42 | The effect of inhaled nitric oxide on the carrageenan-induced paw edema. ( Borbely, AU; Coelho, CF; Frigo, L; Gouvea, IM; Lopes-Martins, PS; Lopes-Martins, RÁ; Teixeira, SA; Vieira, RP, 2015) |
| "Rolipram was effective in inhibiting angiogenesis as assessed by hemoglobin content and VEGF levels in subcutaneous implants (about 40% with both doses) but failed to exert this activity in intraperitoneal implants." | 1.35 | Differential effects of rolipram on chronic subcutaneous inflammatory angiogenesis and on peritoneal adhesion in mice. ( Andrade, SP; Araújo, FA; Ferreira, MA; Mendes, JB; Moura, SA; Rocha, MA, 2009) |
| "Renal interstitial inflammation is a consequence of unilateral ureteral obstruction (UUO)." | 1.33 | A2A adenosine receptor agonist and PDE4 inhibition delays inflammation but fails to reduce injury in experimental obstructive nephropathy. ( Chevalier, RL; Forbes, MS; Lange-Sperandio, B; Linden, J; Okusa, MD; Thornhill, B, 2005) |
| " Multiple day dosing also improved activity." | 1.31 | Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models. ( Egging, EA; Gullikson, GW; Hammerbeck, DM; Hupperts, AM; Johnson, DD; McGurran, SM; Radziszewski, PL, 2000) |
| "Pretreatment with rolipram abrogated oedema formation and significantly inhibited hyperalgesia." | 1.31 | Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis. ( Cunha, FQ; Francischi, JN; Poole, S; Tafuri, WL; Teixeira, MM; Yokoro, CM, 2000) |
| "Pulmonary inflammation was induced in adult Wistar rats by a 60-min exposure to endotoxin (lipopolysaccharide, LPS, 100 micrograms/mL)." | 1.30 | Effects of interleukin-10 and modulators of cyclic AMP formation on endotoxin-induced inflammation in rat lung. ( Boichot, E; Escofier, N; Germain, N; Lagente, V; Martins, MA; Silva, PM, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (16.67) | 18.2507 |
| 2000's | 24 (44.44) | 29.6817 |
| 2010's | 17 (31.48) | 24.3611 |
| 2020's | 4 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Andrés, JI | 1 |
| Alonso, JM | 1 |
| Díaz, A | 1 |
| Fernández, J | 1 |
| Iturrino, L | 1 |
| Martínez, P | 1 |
| Matesanz, E | 1 |
| Freyne, EJ | 1 |
| Deroose, F | 1 |
| Boeckx, G | 1 |
| Petit, D | 1 |
| Diels, G | 1 |
| Megens, A | 1 |
| Somers, M | 1 |
| Van Wauwe, J | 1 |
| Stoppie, P | 1 |
| Cools, M | 1 |
| De Clerck, F | 1 |
| Peeters, D | 1 |
| de Chaffoy, D | 1 |
| Kim, E | 1 |
| Chun, HO | 1 |
| Jung, SH | 1 |
| Kim, JH | 1 |
| Lee, JM | 1 |
| Suh, BC | 1 |
| Xiang, MX | 1 |
| Rhee, CK | 1 |
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Wang, Z | 1 |
| Wang, Y | 1 |
| Wang, B | 1 |
| Li, W | 1 |
| Huang, L | 1 |
| Li, X | 1 |
| Bollenbach, M | 1 |
| Salvat, E | 1 |
| Daubeuf, F | 1 |
| Wagner, P | 1 |
| Yalcin, I | 1 |
| Humo, M | 1 |
| Letellier, B | 1 |
| Becker, LJ | 1 |
| Bihel, F | 1 |
| Bourguignon, JJ | 1 |
| Villa, P | 1 |
| Obrecht, A | 1 |
| Frossard, N | 1 |
| Barrot, M | 1 |
| Schmitt, M | 1 |
| Blöcher, R | 1 |
| Wagner, KM | 1 |
| Gopireddy, RR | 1 |
| Harris, TR | 1 |
| Wu, H | 1 |
| Barnych, B | 1 |
| Hwang, SH | 1 |
| Xiang, YK | 1 |
| Proschak, E | 1 |
| Morisseau, C | 1 |
| Hammock, BD | 1 |
| Ručilová, V | 1 |
| Świerczek, A | 1 |
| Vanda, D | 1 |
| Funk, P | 1 |
| Lemrová, B | 1 |
| Gawalska, A | 1 |
| Bucki, A | 1 |
| Nowak, B | 1 |
| Zadrożna, M | 1 |
| Pociecha, K | 1 |
| Soural, M | 1 |
| Wyska, E | 1 |
| Pawłowski, M | 1 |
| Chłoń-Rzepa, G | 1 |
| Zajdel, P | 1 |
| Lu, X | 1 |
| Wang, J | 1 |
| Chen, X | 1 |
| Jiang, Y | 1 |
| Pan, ZK | 1 |
| Sousa, LP | 1 |
| Pinho, V | 1 |
| Teixeira, MM | 3 |
| Rochford, I | 1 |
| Joshi, JC | 1 |
| Rayees, S | 1 |
| Anwar, M | 1 |
| Akhter, MZ | 1 |
| Yalagala, L | 1 |
| Banerjee, S | 1 |
| Mehta, D | 1 |
| Avila, DV | 1 |
| Myers, SA | 1 |
| Zhang, J | 1 |
| Kharebava, G | 1 |
| McClain, CJ | 1 |
| Kim, HY | 1 |
| Whittemore, SR | 1 |
| Gobejishvili, L | 1 |
| Barve, S | 1 |
| Watremez, W | 1 |
| Jackson, J | 1 |
| Almari, B | 1 |
| McLean, SL | 1 |
| Grayson, B | 1 |
| Neill, JC | 1 |
| Fischer, N | 1 |
| Allouche, A | 1 |
| Koziel, V | 1 |
| Pillot, T | 1 |
| Harte, MK | 1 |
| Graf, R | 1 |
| Longo, JL | 1 |
| Hughes, ZA | 1 |
| Yang, JX | 1 |
| Hsiung, TC | 1 |
| Weng, FC | 1 |
| Ding, SL | 1 |
| Wu, CP | 1 |
| Conti, M | 2 |
| Chuang, TH | 1 |
| Catherine Jin, SL | 1 |
| Korhonen, R | 1 |
| Hömmö, T | 1 |
| Keränen, T | 1 |
| Laavola, M | 1 |
| Hämäläinen, M | 1 |
| Vuolteenaho, K | 1 |
| Lehtimäki, L | 1 |
| Kankaanranta, H | 1 |
| Moilanen, E | 1 |
| Rutter, AR | 1 |
| Poffe, A | 1 |
| Cavallini, P | 1 |
| Davis, TG | 1 |
| Schneck, J | 1 |
| Negri, M | 1 |
| Vicentini, E | 1 |
| Montanari, D | 1 |
| Arban, R | 1 |
| Gray, FA | 1 |
| Davies, CH | 1 |
| Wren, PB | 1 |
| Coelho, CF | 1 |
| Vieira, RP | 1 |
| Lopes-Martins, PS | 1 |
| Teixeira, SA | 1 |
| Borbely, AU | 1 |
| Gouvea, IM | 1 |
| Frigo, L | 1 |
| Lopes-Martins, RÁ | 1 |
| Lee, DU | 1 |
| Shin, DM | 1 |
| Hong, JH | 1 |
| Kumar, A | 1 |
| Singh, N | 1 |
| Méhats, C | 2 |
| Franco-Montoya, ML | 1 |
| Boucherat, O | 1 |
| Lopez, E | 1 |
| Schmitz, T | 2 |
| Zana, E | 1 |
| Evain-Brion, D | 2 |
| Bourbon, J | 1 |
| Delacourt, C | 1 |
| Jarreau, PH | 1 |
| Dastidar, SG | 1 |
| Ray, A | 1 |
| Shirumalla, R | 1 |
| Rajagopal, D | 1 |
| Chaudhary, S | 1 |
| Nanda, K | 1 |
| Sharma, P | 1 |
| Seth, MK | 1 |
| Balachandran, S | 1 |
| Gupta, N | 1 |
| Palle, V | 1 |
| Dozier, KC | 1 |
| Cureton, EL | 1 |
| Kwan, RO | 1 |
| Curran, B | 1 |
| Sadjadi, J | 1 |
| Victorino, GP | 1 |
| Pruniaux, MP | 2 |
| Lagente, V | 3 |
| Ouaged, M | 1 |
| Bertin, B | 1 |
| Moreau, F | 1 |
| Julien-Larose, C | 1 |
| Rocher, MN | 1 |
| Leportier, C | 1 |
| Martin, B | 1 |
| Bouget, A | 1 |
| Dubuit, JP | 1 |
| Burnouf, C | 1 |
| Doherty, AM | 1 |
| Bertrand, CP | 2 |
| Mendes, JB | 1 |
| Rocha, MA | 1 |
| Araújo, FA | 1 |
| Moura, SA | 1 |
| Ferreira, MA | 1 |
| Andrade, SP | 1 |
| Bielekova, B | 1 |
| Richert, N | 1 |
| Howard, T | 1 |
| Packer, AN | 1 |
| Blevins, G | 1 |
| Ohayon, J | 1 |
| McFarland, HF | 1 |
| Stürzebecher, CS | 1 |
| Martin, R | 1 |
| Shen, JJ | 1 |
| Chiang, MS | 1 |
| Kuo, ML | 1 |
| Leu, YL | 1 |
| Hwang, TL | 1 |
| Liou, CJ | 1 |
| Huang, WC | 1 |
| Kenk, M | 1 |
| Thomas, A | 1 |
| Lortie, M | 1 |
| Dekemp, R | 1 |
| Beanlands, RS | 1 |
| Dasilva, JN | 1 |
| Schick, MA | 1 |
| Wunder, C | 1 |
| Wollborn, J | 1 |
| Roewer, N | 1 |
| Waschke, J | 1 |
| Germer, CT | 1 |
| Schlegel, N | 1 |
| Torres-López, JE | 1 |
| Argüelles, CF | 1 |
| Granados-Soto, V | 1 |
| Monneret, G | 1 |
| Arpin, M | 1 |
| Venet, F | 1 |
| Maghni, K | 1 |
| Debard, AL | 1 |
| Pachot, A | 1 |
| Lepape, A | 1 |
| Bienvenu, J | 1 |
| Devillier, P | 1 |
| Block, F | 1 |
| Loos, M | 1 |
| Frohn, C | 1 |
| Schwarz, M | 1 |
| Shukuri, M | 1 |
| Terai, M | 1 |
| Hosoi, R | 1 |
| Nishimura, T | 1 |
| Gee, A | 1 |
| Inoue, O | 1 |
| Castro, A | 1 |
| Jerez, MJ | 1 |
| Gil, C | 1 |
| Martinez, A | 1 |
| Ariga, M | 1 |
| Neitzert, B | 1 |
| Nakae, S | 1 |
| Mottin, G | 1 |
| Bertrand, C | 1 |
| Jin, SL | 1 |
| Lange-Sperandio, B | 1 |
| Forbes, MS | 1 |
| Thornhill, B | 1 |
| Okusa, MD | 1 |
| Linden, J | 1 |
| Chevalier, RL | 1 |
| Nejman-Gryz, P | 1 |
| Grubek-Jaworska, H | 1 |
| Glapiński, J | 1 |
| Hoser, G | 1 |
| Chazan, R | 1 |
| Souil, E | 1 |
| Hervé, R | 1 |
| Nicco, C | 1 |
| Batteux, F | 1 |
| Germain, G | 1 |
| Cabrol, D | 1 |
| Leroy, MJ | 1 |
| Nénan, S | 1 |
| Planquois, JM | 1 |
| Hitier, S | 1 |
| Berna, P | 1 |
| Boichot, E | 2 |
| de Visser, YP | 1 |
| Walther, FJ | 1 |
| Laghmani, EH | 1 |
| van Wijngaarden, S | 1 |
| Nieuwland, K | 1 |
| Wagenaar, GT | 1 |
| Arvin, B | 1 |
| Neville, LF | 1 |
| Barone, FC | 1 |
| Feuerstein, GZ | 1 |
| Griswold, DE | 2 |
| Webb, EF | 1 |
| Breton, J | 1 |
| White, JR | 1 |
| Marshall, PJ | 1 |
| Torphy, TJ | 1 |
| Sekut, L | 1 |
| Yarnall, D | 1 |
| Stimpson, SA | 1 |
| Noel, LS | 1 |
| Bateman-Fite, R | 1 |
| Clark, RL | 1 |
| Brackeen, MF | 1 |
| Menius, JA | 1 |
| Connolly, KM | 1 |
| Santing, RE | 1 |
| Olymulder, CG | 1 |
| Van der Molen, K | 1 |
| Meurs, H | 1 |
| Zaagsma, J | 1 |
| Raeburn, D | 1 |
| Underwood, SL | 1 |
| Lewis, SA | 1 |
| Woodman, VR | 1 |
| Battram, CH | 1 |
| Tomkinson, A | 1 |
| Sharma, S | 1 |
| Jordan, R | 1 |
| Souness, JE | 1 |
| Webber, SE | 1 |
| Tzimas, MN | 1 |
| Klemm, P | 1 |
| Harris, HJ | 1 |
| Perretti, M | 1 |
| Escofier, N | 1 |
| Germain, N | 1 |
| Silva, PM | 1 |
| Martins, MA | 1 |
| Cunha, FQ | 2 |
| Ferreira, SH | 1 |
| Hammerbeck, DM | 1 |
| McGurran, SM | 1 |
| Radziszewski, PL | 1 |
| Egging, EA | 1 |
| Johnson, DD | 1 |
| Hupperts, AM | 1 |
| Gullikson, GW | 1 |
| Francischi, JN | 1 |
| Yokoro, CM | 1 |
| Poole, S | 1 |
| Tafuri, WL | 1 |
| Kanehiro, A | 1 |
| Ikemura, T | 1 |
| Mäkelä, MJ | 1 |
| Lahn, M | 1 |
| Joetham, A | 1 |
| Dakhama, A | 1 |
| Gelfand, EW | 1 |
| Eigler, A | 1 |
| Loher, F | 1 |
| Endres, S | 1 |
| Spond, J | 1 |
| Chapman, R | 1 |
| Fine, J | 1 |
| Jones, H | 1 |
| Kreutner, W | 1 |
| Kung, TT | 1 |
| Minnicozzi, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)[NCT04570449] | Early Phase 1 | 0 participants (Actual) | Interventional | 2020-11-30 | Withdrawn (stopped due to Study timeline is not feasible) | ||
| Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis[NCT05080270] | Early Phase 1 | 5 participants (Actual) | Interventional | 2020-09-21 | Completed | ||
| Regeneration in Cervical Degenerative Myelopathy - a Multi-centre, Double-blind, Randomised, Placebo Controlled Trial Assessing the Efficacy of Ibudilast as an Adjuvant Treatment to Decompressive Surgery for Degenerative Cervical Myelopathy[NCT04631471] | Phase 3 | 400 participants (Anticipated) | Interventional | 2021-12-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for rolipram and Innate Inflammatory Response
| Article | Year |
|---|---|
Phenylpyridine-2-ylguanidines and rigid mimetics as novel inhibitors of TNFα overproduction: Beneficial action in models of neuropathic pain and of acute lung inflammation.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents, Non-Steroidal; Guanidines; Humans; Inflammatio | 2018 |
Harnessing inflammation resolving-based therapeutic agents to treat pulmonary viral infections: What can the future offer to COVID-19?
Topics: Acetates; Angiotensin I; Animals; Annexin A1; Anti-Inflammatory Agents; COVID-19; COVID-19 Drug Trea | 2020 |
PET measurements of cAMP-mediated phosphodiesterase-4 with (R)-[11C]rolipram.
Topics: Animals; Asthma; Brain; Carbon Radioisotopes; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type | 2011 |
[Physiopathology of COPD: choosing the right therapeutic targets].
Topics: Adrenal Cortex Hormones; Aged; Albuterol; Animals; Bacterial Infections; Bronchodilator Agents; Carb | 2003 |
Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Autoimmune Diseases; Cyclic AMP; Cyclic Nucleotide Pho | 2005 |
Brain injury and inflammation. A putative role of TNF alpha.
Topics: Animals; Brain Injuries; Calcium; Cell Adhesion; Cell Adhesion Molecules; Cell Death; Central Nervou | 1995 |
[Suppression of synthesis of tumor necrosis factor].
Topics: Animals; Arthritis, Rheumatoid; Crohn Disease; Humans; Inflammation; Interleukin-10; Phosphodiestera | 2001 |
1 trial available for rolipram and Innate Inflammatory Response
| Article | Year |
|---|---|
Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis.
Topics: Biomarkers; Blood-Brain Barrier; Cell Proliferation; Contrast Media; Humans; Immunophenotyping; Infl | 2009 |
46 other studies available for rolipram and Innate Inflammatory Response
| Article | Year |
|---|---|
Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Topical; Animals; Anti-Inflammatory Agents; Cyc | 2002 |
Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-Asthmatics.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Anti-Asthmatic Agents; Binding Sites; Brain; Bronchoal | 2003 |
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Design, Synthesis, and Evaluation of Orally Available Clioquinol-Moracin M Hybrids as Multitarget-Directed Ligands for Cognitive Improvement in a Rat Model of Neurodegeneration in Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Clioquinol; Cognition; | 2015 |
Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain.
Topics: Administration, Oral; Analgesics; Animals; Epoxide Hydrolases; HEK293 Cells; Humans; Inflammation; L | 2018 |
New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
Topics: Animals; Anti-Inflammatory Agents; Autoimmune Diseases; Cyclic Nucleotide Phosphodiesterases, Type 7 | 2021 |
Rolipram Protects Mice from Gram-negative Bacterium Escherichia coli-induced Inflammation and Septic Shock.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Escherichia coli; Escherichia coli Infections; Inflamm | 2020 |
Evidence for reprogramming of monocytes into reparative alveolar macrophages in vivo by targeting PDE4b.
Topics: Acute Lung Injury; Adoptive Transfer; Animals; Capillary Permeability; Cell Differentiation; Cyclic | 2021 |
Phosphodiesterase 4b expression plays a major role in alcohol-induced neuro-inflammation.
Topics: Alcohol-Related Disorders; Animals; Astrocytes; Brain; Cells, Cultured; Central Nervous System Depre | 2017 |
Stabilized Low-n Amyloid-β Oligomers Induce Robust Novel Object Recognition Deficits Associated with Inflammatory, Synaptic, and GABAergic Dysfunction in the Rat.
Topics: Amyloid beta-Peptides; Animals; Brain; Cognition; Disease Models, Animal; Donepezil; Female; gamma-A | 2018 |
The location discrimination reversal task in mice is sensitive to deficits in performance caused by aging, pharmacological and other challenges.
Topics: Aging; Animals; Conditioning, Operant; Discrimination, Psychological; Dizocilpine Maleate; Donepezil | 2018 |
Synergistic effect of phosphodiesterase 4 inhibitor and serum on migration of endotoxin-stimulated macrophages.
Topics: Animals; Cell Movement; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Inflammation; Lipo | 2018 |
Attenuation of TNF production and experimentally induced inflammation by PDE4 inhibitor rolipram is mediated by MAPK phosphatase-1.
Topics: Animals; Carrageenan; Cell Line; Dual Specificity Phosphatase 1; Inflammation; Macrophages; Mice; Mi | 2013 |
GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species.
Topics: Aminopyridines; Animals; Anti-Anxiety Agents; Behavior, Animal; Benzamides; Callithrix; Cerebral Cor | 2014 |
The effect of inhaled nitric oxide on the carrageenan-induced paw edema.
Topics: Animals; Carrageenan; Edema; Inflammation; Male; Mice; Nitric Oxide; Piperazines; Purines; Rolipram; | 2015 |
The Regulatory Role of Rolipram on Inflammatory Mediators and Cholinergic/Adrenergic Stimulation-Induced Signals in Isolated Primary Mouse Submandibular Gland Cells.
Topics: Animals; Calcium Signaling; Cells, Cultured; Histamine; Inflammation; Lipopolysaccharides; Mice; Rea | 2016 |
Inhibitor of Phosphodiestearse-4 improves memory deficits, oxidative stress, neuroinflammation and neuropathological alterations in mouse models of dementia of Alzheimer's Type.
Topics: Acetylcholinesterase; Aging; Alzheimer Disease; Animals; Antioxidants; Brain; Cholinesterase Inhibit | 2017 |
Effects of phosphodiesterase 4 inhibition on alveolarization and hyperoxia toxicity in newborn rats.
Topics: Animals; Animals, Newborn; Hyperoxia; Inflammation; Lung Injury; Phosphodiesterase 4 Inhibitors; Pho | 2008 |
Pharmacology of a novel, orally active PDE4 inhibitor.
Topics: Animals; Carboxylic Acids; Cell Line, Transformed; Cyclic AMP; Cyclohexanecarboxylic Acids; Disease | 2009 |
Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation.
Topics: Animals; Capillary Permeability; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dideoxyadenosine; | 2009 |
Relationship between phosphodiesterase type 4 inhibition and anti-inflammatory activity of CI-1044 in rat airways.
Topics: Administration, Oral; Animals; Azepines; Carboxylic Acids; Cyclohexanecarboxylic Acids; Disease Mode | 2010 |
Differential effects of rolipram on chronic subcutaneous inflammatory angiogenesis and on peritoneal adhesion in mice.
Topics: Administration, Oral; Animals; Chemokine CCL2; Collagen; Disease Models, Animal; Fibrosis; Inflammat | 2009 |
Partially purified extract and viscolin from Viscum coloratum attenuate airway inflammation and eosinophil infiltration in ovalbumin-sensitized mice.
Topics: Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Biphenyl Compounds; Bronchial Hyperreactiv | 2011 |
Phosphodiesterase-4 inhibition as a therapeutic approach to treat capillary leakage in systemic inflammation.
Topics: Aminopyridines; Animals; Benzamides; Capillaries; Capillary Permeability; Cyclic AMP; Cyclopropanes; | 2012 |
Participation of peripheral and spinal phosphodiesterases 4 and 5 in inflammatory pain.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Cyclic Nucleotide | 2002 |
Calcitonin gene related peptide and N-procalcitonin modulate CD11b upregulation in lipopolysaccharide activated monocytes and neutrophils.
Topics: Biomarkers; Calcitonin; Calcitonin Gene-Related Peptide; CD11b Antigen; Cells, Cultured; Chemotaxis, | 2003 |
Association between inflammation and nigral neuronal damage following striatal excitotoxic lesion.
Topics: Animals; Brain Diseases; Cell Count; Chondroitin Sulfate Proteoglycans; Corpus Striatum; Dizocilpine | 2004 |
Effect of rolipram on relative 14C-deoxyglucose uptake in inflammatory lesions and skeletal muscle.
Topics: Animals; Deoxyglucose; Drug Combinations; Image Enhancement; Inflammation; Injections, Intraperitone | 2005 |
Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cell Adhesion; Chemokines; Chemotaxis, Leukocyte; Cycl | 2004 |
A2A adenosine receptor agonist and PDE4 inhibition delays inflammation but fails to reduce injury in experimental obstructive nephropathy.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Apoptosis; Cell Proliferation; Cyclic Nucleotide Phosp | 2005 |
Effects of the phosphodiestrase-4 inhibitor rolipram on lung resistance and inflammatory reaction in experimental asthma.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; Dexamethasone; Guinea Pigs; | 2006 |
PDE4 inhibition prevents preterm delivery induced by an intrauterine inflammation.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Amniotic Fluid; Animals; Cell Movement; Cervical Ripening; Cycl | 2007 |
Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat.
Topics: Animals; Bronchoalveolar Lavage Fluid; Chemokines; Cytokines; Dexamethasone; Enzyme Inhibitors; Gluc | 2007 |
Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury.
Topics: Animals; Animals, Newborn; Benzamides; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Gene Ex | 2008 |
Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic A | 1993 |
Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Carrageenan; Female; Gala | 1995 |
Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Inhalation; Analysis of Variance; Animals; Asth | 1995 |
Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor.
Topics: Albuterol; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Bronchial Hyperreactivity; | 1994 |
Ultraviolet B-induced inflammatory cytokine production, in vivo: initial pharmacological characterization.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cytokines; Dose-Response Relationship, Radiation; | 1995 |
Effect of rolipram in a murine model of acute inflammation: comparison with the corticoid dexamethasone.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Dexametha | 1995 |
Effects of interleukin-10 and modulators of cyclic AMP formation on endotoxin-induced inflammation in rat lung.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Animals; Bronchoalveolar Lavage Flu | 1999 |
Pharmacological modulation of secondary mediator systems--cyclic AMP and cyclic GMP--on inflammatory hyperalgesia.
Topics: Animals; Bradykinin; Carrageenan; Cyclic AMP; Cyclic GMP; Dinoprostone; Dopamine; Hyperalgesia; Infl | 1999 |
Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Androstadienes; Animals; Asthma; Beclomethasone; Benzamides; Bu | 2000 |
Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Analgesics; Animals; Anti-Inflammatory Agents; Arthritis, Exper | 2000 |
Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge.
Topics: Airway Resistance; Allergens; Animals; Bronchoalveolar Lavage Fluid; Female; Inflammation; Integrin | 2001 |
Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia.
Topics: Adrenalectomy; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Humans; Inflammation; I | 2001 |